BACKGROUND: Familial colorectal cancer type X (FCCTX) fulfils clinical criteria defining Lynch syndrome (LS), but is not related to germline mutations in DNA mismatch-repair genes. Its aetiology remains unexplained and there is little evidence of involvement of the common colorectal carcinogenetic pathways. We aimed to identify susceptibility loci and gain insights into carcinogenic pathways involved FCCTX tumour development. METHODS: We performed a linkage analysis in 22 FCCTX families. We also constructed a tissue microarray in order to define an immunohistochemical (IHC) profile for FCCTX tumours (N = 27) by comparing them to three other types of colorectal tumors: LS (N = 18), stable early-onset (N = 31) and other sporadic disease (N = 80). Additionally, we screened for BRAF/KRAS mutations and determined CpG island methylator phenotype (CIMP) status for all FCCTX tumours. RESULTS: We found suggestive evidence of linkage at four chromosomal regions; 2p24.3, 4q13.1, 4q31.21 and 12q21.2-q21.31. We screened genes in 12q21 and ruled out the implication of RASSF9 and NTS, good candidates due to their potential involvement in carcinogenesis and colorectal epithelium development. Based on IHC profiles FCCTX tumours did not form a single, exclusive cluster. They were clearly different from LS, but very similar to stable early onset tumours. The CIMP and chromosomal instability pathways were implicated in one-third and one-quarter of FCCTX cases, respectively. The remaining cases did not have alterations in any known carcinogenic pathways. CONCLUSIONS: Our results highlight the heterogeneity of FCCTX tumours and call into question the utility of using only clinical criteria to identify FCCTX cases.
BACKGROUND:Familial colorectal cancer type X (FCCTX) fulfils clinical criteria defining Lynch syndrome (LS), but is not related to germline mutations in DNA mismatch-repair genes. Its aetiology remains unexplained and there is little evidence of involvement of the common colorectal carcinogenetic pathways. We aimed to identify susceptibility loci and gain insights into carcinogenic pathways involved FCCTXtumour development. METHODS: We performed a linkage analysis in 22 FCCTX families. We also constructed a tissue microarray in order to define an immunohistochemical (IHC) profile for FCCTXtumours (N = 27) by comparing them to three other types of colorectal tumors: LS (N = 18), stable early-onset (N = 31) and other sporadic disease (N = 80). Additionally, we screened for BRAF/KRAS mutations and determined CpG island methylator phenotype (CIMP) status for all FCCTXtumours. RESULTS: We found suggestive evidence of linkage at four chromosomal regions; 2p24.3, 4q13.1, 4q31.21 and 12q21.2-q21.31. We screened genes in 12q21 and ruled out the implication of RASSF9 and NTS, good candidates due to their potential involvement in carcinogenesis and colorectal epithelium development. Based on IHC profiles FCCTXtumours did not form a single, exclusive cluster. They were clearly different from LS, but very similar to stable early onset tumours. The CIMP and chromosomal instability pathways were implicated in one-third and one-quarter of FCCTX cases, respectively. The remaining cases did not have alterations in any known carcinogenic pathways. CONCLUSIONS: Our results highlight the heterogeneity of FCCTXtumours and call into question the utility of using only clinical criteria to identify FCCTX cases.
Authors: Laura Valle; Jose Perea; Pablo Carbonell; Victoria Fernandez; Ana M Dotor; Javier Benitez; Miguel Urioste Journal: J Clin Oncol Date: 2007-01-16 Impact factor: 44.544
Authors: S Ogino; M Cantor; T Kawasaki; M Brahmandam; G J Kirkner; D J Weisenberger; M Campan; P W Laird; M Loda; C S Fuchs Journal: Gut Date: 2006-01-11 Impact factor: 23.059
Authors: Courtney Gray-McGuire; Kishore Guda; Indra Adrianto; Chee Paul Lin; Leanna Natale; John D Potter; Polly Newcomb; Elizabeth M Poole; Cornelia M Ulrich; Noralane Lindor; Ellen L Goode; Brooke L Fridley; Robert Jenkins; Loic Le Marchand; Graham Casey; Robert Haile; John Hopper; Mark Jenkins; Joanne Young; Daniel Buchanan; Steve Gallinger; Mark Adams; Susan Lewis; Joseph Willis; Robert Elston; Sanford D Markowitz; Georgia L Wiesner Journal: Cancer Res Date: 2010-06-15 Impact factor: 12.701
Authors: Eli Papaemmanuil; Luis Carvajal-Carmona; Gabrielle S Sellick; Zoe Kemp; Emily Webb; Sarah Spain; Kate Sullivan; Ella Barclay; Steven Lubbe; Emma Jaeger; Jayaram Vijayakrishnan; Peter Broderick; Maggie Gorman; Lynn Martin; Anneke Lucassen; D Timothy Bishop; D Gareth Evans; Eamonn R Maher; Verena Steinke; Nils Rahner; Hans K Schackert; Timm O Goecke; Elke Holinski-Feder; Peter Propping; Tom Van Wezel; Juul Wijnen; Jean-Baptiste Cazier; Huw Thomas; Richard S Houlston; Ian Tomlinson Journal: Eur J Hum Genet Date: 2008-07-16 Impact factor: 4.246
Authors: J Skoglund; T Djureinovic; X-L Zhou; J Vandrovcova; E Renkonen; L Iselius; M L Bisgaard; P Peltomäki; A Lindblom Journal: J Med Genet Date: 2006-02 Impact factor: 6.318
Authors: Deborah W Neklason; Richard A Kerber; David B Nilson; Hoda Anton-Culver; Ann G Schwartz; Constance A Griffin; Jan T Lowery; Joellen M Schildkraut; James P Evans; Gail E Tomlinson; Louise C Strong; Alexander R Miller; Jill E Stopfer; Dianne M Finkelstein; Prakash M Nadkarni; Carol H Kasten; Geraldine P Mineau; Randall W Burt Journal: Cancer Res Date: 2008-11-01 Impact factor: 12.701
Authors: Emmi I Joensuu; Wael M Abdel-Rahman; Miina Ollikainen; Salla Ruosaari; Sakari Knuutila; Päivi Peltomäki Journal: Cancer Res Date: 2008-06-15 Impact factor: 12.701
Authors: Henry T Lynch; Stephen Lanspa; Trudy Shaw; Murray Joseph Casey; Marc Rendell; Mark Stacey; Theresa Townley; Carrie Snyder; Megan Hitchins; Joan Bailey-Wilson Journal: Fam Cancer Date: 2018-07 Impact factor: 2.375
Authors: José Perea; Juana M Cano; Daniel Rueda; Juan L García; Lucía Inglada; Irene Osorio; María Arriba; Jessica Pérez; Miriam Gaspar; Tamara Fernández-Miguel; Yolanda Rodríguez; Javier Benítez; Rogelio González-Sarmiento; Miguel Urioste Journal: Am J Cancer Res Date: 2015-06-15 Impact factor: 6.166
Authors: Salem Werdyani; Yajun Yu; Georgia Skardasi; Jingxiong Xu; Konstantin Shestopaloff; Wei Xu; Elizabeth Dicks; Jane Green; Patrick Parfrey; Yildiz E Yilmaz; Sevtap Savas Journal: Cancer Med Date: 2017-05-23 Impact factor: 4.452
Authors: Felipe Antonio de Oliveira Garcia; Edilene Santos de Andrade; Henrique de Campos Reis Galvão; Cristina da Silva Sábato; Natália Campacci; Andre Escremin de Paula; Adriane Feijó Evangelista; Iara Viana Vidigal Santana; Matias Eliseo Melendez; Rui Manuel Reis; Edenir Inez Palmero Journal: Sci Rep Date: 2022-02-18 Impact factor: 4.379